Q2 2023 Eton Pharmaceuticals Inc Earnings Call
Participants
David Krempa; Chief Business Officer; Eton Pharmaceuticals, Inc.
Sean Brynjelsen; CEO & Director; Eton Pharmaceuticals, Inc.
James Gruber; CFO; Eton Pharmaceuticals, Inc.
Raghuram Selvaraju; Analyst; H.C. Wainwright
Presentation
Operator
Good afternoon, and welcome to Eton Pharmaceuticals' second-quarter 2023 financial results conference call. (Operator Instructions)
Please be advised that this call is being recorded at the company's request.
At this time, I'd like to turn it over to David Krempa, Chief Business Officer at Eton Pharmaceuticals. Please go ahead.
David Krempa
Thank you, operator. Good afternoon, everyone, and welcome to Eton's second quarter of 2023 conference call. This afternoon, we issued a press release that outlines the topics we plan to discuss on today's call. The release is available on our website, etonpharma.com.
Joining me on our call today, we have Sean Brynjelsen, our CEO; and James Gruber, our CFO. In addition to taking live questions on today's call, we will be answering questions that are e-mailed to us. You can send your questions to Investor Relations at etonpharma.com.
Before we begin, I would like to remind everyone that remarks made during today's call may contain forward-looking statements and involve risks and uncertainties that could cause actual results to differ materially from those contained in these forward-looking statements. Please see the forward-looking statements disclaimer in our earnings release and the risk factors in the company's filings with the SEC.
Now I will turn the call over to our CEO, Sean Brynjelsen.
Sean Brynjelsen
Thank you, David. Good afternoon, everyone, and thank you for joining us today. Second quarter was another exceptional quarter for Eton. We delivered record product sales of ALKINDI SPRINKLE and carglumic acid. We launched our third commercial product, betaine anhydrous, and we also recorded positive cash flow and net income. It was our 10th straight quarter of sequential product growth.
As a result of the soft performance through the first half of this year, we are now increasing our revenue expectation for 2023. We expect total 2023 revenue of approximately $30 million. During the second quarter, total revenue was $12 million and net income was $4.6 million. Product sales and royalty revenue were $6.5 million for the quarter, up 176% from the second quarter of 2022 and up 22% sequentially from the first quarter of 2023.
For ALKINDI, our expanded sales force and our direct-to-consumer marketing campaign have continued to help increase engagement with the adrenal insufficiency community. We continue to add patients each week, and our goal is to reach 400 active patients by the end of the year. Even with this fast rate of growth and significant patient base, we are still in the very early stages of the ALKINDI growth story.
With an estimated total pediatric adrenal insufficiency patient population of 10,000 patients, a very large percentage of the market has yet to convert. We believe ALKINDI SPRINKLE on its own should continue to convert a significant portion of this market in the coming months and years. However, our ET-400 product is expected to turbocharge this effort when it is launched.
ET-400 will be sold along ALKINDI SPRINKLE as a new liquid dosage form of hydrocortisone. Patients will choose to take either ALKINDI SPRINKLE or ET-400. ET-400's proprietary patent-pending formulation will address the texture issue that some young patients have reported with sprinkles. And in addition, it will help us convert a large portion of the patient population that is currently using unapproved compounded suspensions.
We expect the combined peak sales of ET-400 and ALKINDI SPRINKLE to exceed $50 million annually. We plan to submit the NDA for ET-400 at the end of this year, which should allow for an approval and commercial launch in late 2024.
Moving now to carglumic acid. Carglumic acid has also had a very strong quarter and the product revenue continues to benefit from our expanded sales force. Our product has continuously outperformed our own expectations, and we remain optimistic that the product will continue to grow nicely for the foreseeable future.
We also launched betaine anhydrous in May, which shares the same prescriber base as carglumic. The betaine launch has increased our interactions with metabolic geneticists and helped us gain access to some hard-to-reach carglumic prescribers.
The betaine launch is progressing well. We are now three months into the launch and have seen significant adoption. We've heard positive feedback both for patients and prescribers that are very appreciative to be able to enroll in our Eton Cares patient support services.
While betaine is the smallest of our three current products, once ramped up, we expect it to contribute multiple millions of revenue annually with minimal incremental costs or resource usage.
Before we move on, let me address the recent CRL we received for dehydrated alcohol. The CRL is primarily related to chemistry manufacturing control items as well as some minor labeling comments. The good news is we do not see a need to conduct additional laboratory activities to address these comments.
We intend to file a response over the coming months, but we think the FDA's issues are addressable. We are disappointed to not have the revenue from this product this year. However, the outperformance in our other products has more than made up for most of the alcohol revenue we were anticipating in 2023. We expect our existing product sale to allow us to reach the cash flow breakeven around the end of this year.
During the quarter, we saw progress with the development of ET-600, which is another innovative product candidate that shares ALKINDI's user base. Physicians have repeatedly expressed the need for this product, which we treat a rare pediatric endocrinology condition called diabetes insipidus. Registration batches have been successfully manufactured so we expect to file the NDA in the middle of 2024.
While our existing commercial products and pipeline are expected to provide us with a long runway of organic growth for many years to come, we continually and aggressively pursue acquisition opportunities to expand our rare disease portfolio even further. We are excited about the prospects for transactions in the coming quarters for three important reasons.
First, our financial position has never been better. We finished the quarter with more than $21 million of cash, one of our highest levels ever. And more importantly perhaps, we expect to reach cash flow breakeven within the coming months. This means that nearly all of our cash balance is excess cash that can be put towards acquiring rare disease products.
Secondly, we are seeing an increasing number of distressed sellers. Due to the challenging capital markets environment, many of our peers are struggling to raise capital. As a result, many companies are no longer able to raise the money needed to commercialize assets. Many others are seeking to sell off products to raise capital or even filing for bankruptcy.
We have already seen a number of attractive assets up for sale from distressed sellers. And we expect to see even more in the coming quarters. With a strong financial position, we believe we are very well positioned to take advantage of these types of opportunities.
And thirdly, with our expanded sales force, we now have an established commercial infrastructure and track record of successfully commercializing niche rare disease products, which makes us an attractive commercial partner. Industry peers have taken notice of our recent results, especially with carglumic acid success. And we have seen an uptick in inbound interest from companies looking for Eton to commercialize their rare disease products.
During the second quarter, we were the stalking horse bidder in a bankruptcy auction for two commercial rare disease products. They were on-market products generating a significant amount of annual revenue. We were ultimately outbid in this. However, even though we did not acquire the assets, we had lined up $50 million in fully committed capital to support our bid.
Given the extremely challenging environment for raising capital, I was proud of our ability to very quickly line up $50 million on attractive terms. Normally, this takes months; it took us a couple of weeks.
I believe lenders were excited by our attractive near- and long-term financial outlook and our diversified portfolio. We believe we have a similar financial resources at our disposal today to pursue other large transactions involving commercial products.
Since we were the stalking horse bidder in that process, we did receive an $800,000 break-up fee. While we would have been much happier if we won the auction, the break-up fee further strengthens our financial position and will help us fund future acquisitions for us.
Also this quarter, we monetized our remaining royalty interest in neurology oral liquid products we previously out-licensed to Azurity. In exchange for selling off our go-forward royalty interest, we received a $5.5 million payment in June. We believe we will be able to reinvest these proceeds into rare disease product opportunities that will yield much higher returns for the company.
This transaction fully closes out all of Eton's future income or liabilities related to those products. In total, during the life of those three products, we received more than $27.5 million in payments after investing approximately only $8 million into the portfolio.
With another record quarter of product sales, strong cash position of more than $21 million, and an attractive pipeline, we believe we are well positioned to deliver sustainable long-term growth. I believe we are now able to reach our goal of achieving 10 rare disease products on-market by the end of 2025.
I'm incredibly proud of our team for working so diligently to get us to where we are today and positioning us for a bright future going forward. It's an exciting time at Eton and I can't wait to update you on our progress throughout the rest of the year.
With that, I'll turn it over to James, our Chief Financial Officer, to discuss the financials. James?
James Gruber
Thank you, Sean. Our second-quarter revenue was $12.0 million compared to $7.4 million in the second quarter of 2022, or a 63% increase, driven entirely by growth in product sales and royalties, specifically increased sales volume for our ALKINDI SPRINKLE and carglumic acid.
Licensing revenue was $5.5 million in the second quarter of 2023 compared to $5.0 million in the prior year period. Total revenue grew $6.7 million or 126% compared to the first quarter of 2023, and product sales and royalty revenue grew by $1.2 million. We expect product sales to continue growing quarter over quarter throughout the rest of this year and beyond.
R&D expenses for the quarter were $1.1 million compared with $0.7 million in the prior year period due primarily to a $0.5 million fee paid upon the successful manufacturing of registration batches of ET-600, the innovative product candidate we acquired last quarter. We expect to see a slight increase in R&D spend in future quarters due to development activities related to both ET-400 and ET-600.
General and administrative expenses for the quarter were $4.7 million compared with $5.3 million in the prior year period due primarily to decreased FDA and legal fees associated with products sold to Dr. Reddy's in June of 2022. We expect expenses to continue to remain consistent throughout the rest of the year and we still anticipate our full-year G&A expense to be approximately $20 million.
Total company net income was $4.6 million for the quarter compared to a net loss of $1.6 million in the prior year period. Net income for basic and diluted share during the quarter was $0.18 compared to a net loss per basic and diluted share of $0.06 in the prior year period.
Eton finished the second quarter with $21.6 million of cash on hand and generated $7.1 million of operating cash during the quarter. We remain confident that our cash position is sufficient to allow us to execute our plan and continue pursuing bolt-on transactions and new product developments.
This concludes our remarks on second-quarter results. And with that, we'll turn it back over to the operator for Q&A.
Question and Answer Session
Operator
Thank you. We will now conduct a question-and-answer session. (Operator Instructions)
Raghuram Selvaraju, H.C. Wainwright.
Raghuram Selvaraju
Hi, thanks very much for taking my questions. Just a few quick ones. Firstly, I was wondering if you could perhaps comment on your criteria and potential timeline for acquisition of new products, if you have some specific areas that you are going to be focusing on, if we should be thinking about these products as being directly complementary to or synergistic with the existing commercial products in your portfolio?
Secondly, I wanted to make sure I fully understood situation with the dehydrated alcohol product and whether you feel that there is going to be an opportunity to prepare for marketing in a more thorough way or do activities or pre-launch that you wouldn't otherwise have been able to do given the new -- the extended timeline to potential market entry.
And then lastly, with respect to the stock-based compensation, I was just wondering if you could point me to any potential trends we should be keeping an eye out for over the course of the remainder of this year. Thank you.
Sean Brynjelsen
Thanks, Ram. Sean here. So regarding M&A activity, I do anticipate closing a deal or two prior to the year, and we hope -- we would say that likely that these products would be a good fit with our existing sales organization and would be accretive to revenue.
Obviously, there's no guarantee of that, but we are in late-stage discussions. I'd say the environment is fantastic in terms of a deal on availability. And I'm not averse to closing a transaction outside of our core competency within endocrinology and metabolic genetics.
But I think the product would have to justify the expenditure of additional SG&A resources. So that's something we're looking at and we'll see what happens.
Maybe, David, you want to take the second question?
David Krempa
In terms of the alcohol, no, Ram, dehydrated alcohol would be marketed by our partner. So we don't have any plans to do anything different based on the additional timeline.
It's a product that, as you know, is already used in the market by almost every hospital. So it's not one that requires a lot of promotion from them. It's mostly going to be ordered through the GPOs and the wholesalers without much promotion.
And your third question, James will answer.
James Gruber
Sure. Yeah. With the stock-based comp, Ram, second quarter was pretty representative. We don't expect anything unusual or one-time in that arena in the second half of 2023. So the most recent quarter would be a good run rate to use.
Raghuram Selvaraju
Okay. And then just very quickly, do you have any additional updates on the legal front with respect to cysteine hydrochloride?
David Krempa
No update at this time. We are expecting a decision sometime into early 2024, but there's no hard timeline that could get delayed. But our best guess is sometime in the first half of 2024.
Raghuram Selvaraju
Great. Thanks very much.
Operator
(Operator Instructions)
I will now pass it over back to David.
David Krempa
Thank you. We have a few questions that were e-mailed to us that we can go through and answer at this time. First one, is there any chance that the FDA may issue a priority review voucher to Eton for ET-600 if the product is approved?
No, we're not expecting any voucher for that product. Typically, the vouchers, among other things, have to be a new molecule. This one is going to be a 505(b)(2). So we're not expecting a voucher.
Second question is: when do you expect to give guidance for 2024 revenue? I will let James answer them.
James Gruber
Sure. Historically, Eton does not provide a full-year guidance in advance. However, with ongoing M&A activity, if there was a transformational transaction in the second half of 2023, we would likely provide some guidance on how that would impact the portfolio going forward.
David Krempa
And the last question we have is: what are your commercial expectations for ET-400? And I'll let Sean answer that one.
Sean Brynjelsen
Thanks. So ET-400 really was a patient-and-doctor request. It was a product that is desperately needed by especially young patients, 2 and below. Sometimes they have trouble with the granularity of the sprinkles. And so they're forced to go to compounding pharmacies to obtain a liquid suspension of hydrocortisone that is not approved for sale. It has no demonstration of safety and efficacy. Also, Pfizer had a liquid version many years ago that had issues and got pulled from the market.
Our product, our hydrocortisone oral solution is room-temperature stable. We expect a 24-month expiration date. And it's a product that we think is really going to drive sales of the franchise. We think there are approximately 10,000 patients, 18 and under, that can benefit from ALKINDI or ET-400. And I feel confident that we'll hit several thousand of those patients with the combination of these two products.
David Krempa
That concludes our questions. Thank you, everyone, for joining us today.
Operator
This concludes today's conference call. Thank you for participating. You may now disconnect.
